Twenty three patients with Cutaneous Larva Migrans syndrome were prospec tively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical respon se, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.
INTRODUCTION
The Syndrome of Cutaneous Larva Migrans (CLM), also known as creeping eruption, is a di sease commonly found in inhabitants of tropical or sub-tropical regions of the world. It is caused by the penetration through the skin of infective larvae from various animal nematodes. Ancylostoma braziliensis, a hookworm of cats and dogs, is responsible for most cases, although other ne matodes such as A. caninum, Uncynaria stenocephala and Bunostomun phlebotomus are oc casionally involved 1 .
Oral thiabendazole at the dose of 25 mg/kg per day for two consecutive days is currently considered the drug of choice. Alternatively, to pical application of an aqueous 10% suspension of the compound (500 mg per 5 ml) or a 0.5 g tablet triturated with 5 g petroleum jelly, has been advocated as equally effective and essen tially devoided of toxic side effects 4 .
MATERIAL AND METHODS
Twenty three patients (sex ratio: 13 males, 
